Azitra brings in $14m Series A to advance microbiome skin therapies
Connecticut-based microbiome therapy company Azitra recently announced a $14 million haul in Series A funding. The round was led by KdT Ventures and previous investor Bios Partners, along with Godfrey Capital and Connecticut Innovations. Azitra, which focuses on dermatologic conditions, will use the funding to expand its team and move therapies into clinical trials.
“We want to leverage the microbiome and take advantage of the contributions that bacteria on our skin make to skin appearance and health, but then amplify it and bring in the ability to deliver therapeutic proteins,” said president and CEO Richard Andrews in a phone interview.